(Q36961822)

17 August 2017

1 reference

title

Challenges in the recruitment of adolescents and young adults to cancer clinical trials (English)

1 reference

17 August 2017

1 reference

Megan E Burke

1

1 reference

17 August 2017

Karen Albritton

series ordinal

2

1 reference

17 August 2017

Neyssa Marina

series ordinal

3

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

110

1 reference

17 August 2017

issue

11

1 reference

17 August 2017

page(s)

2385-2393

1 reference

Cis-Diamminedichloroplatinum, Vinblastine, and Bleomycin Combination Chemotherapy in Disseminated Testicular Cancer

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

The U.S. pediatric cancer clinical trials programmes: international implications and the way forward

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

National cancer clinical trials: children have equal access; adolescents do not.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

The National Cancer Data Base report on patterns of childhood cancers in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

European collaboration in trials of new agents for children with cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

Epidemiologic analysis of 1,442 children and adolescents registered in the German germ cell tumor protocols

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

Recruiting children into cancer trials--role of the United Kingdom Children's Cancer Study Group (UKCCSG)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

Issues surrounding the participation of adolescents with cancer in clinical trials in the UK

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

Adolescents and young adults with cancer: the scope of the problem and criticality of clinical trials.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

Older adolescents with cancer in North America deficits in outcome and research

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

The adolescent and young adult gap in cancer care and outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

Cancer in older adolescents and young adults: epidemiology, diagnosis, treatment, survival, and importance of clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

Pediatric cancer survivors: Past history and future challenges

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

Cancer in 15- to 29-year-olds by primary site

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

Sarcomas in adolescents and young adults

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

Re: Views of American Oncologists About the Purposes of Clinical Trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

National survival trends of young adults with sarcoma: lack of progress is associated with lack of clinical trial participation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

Osteogenic sarcoma with clinically detectable metastasis at initial presentation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

Long-term survival probabilities for childhood rhabdomyosarcoma. A population-based evaluation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery, irradiation, and chemotherapy: a Pediatric Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

Role of adjuvant chemotherapy in the treatment of surgically resected pediatric nonrhabdomyosarcomatous soft tissue sarcomas: A Pediatric Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

Patients with non-seminoma germ cell tumours treated in a minor oncology department: the importance of multi-institutional protocols and research collaboration

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

Poor-prognosis germ cell tumors: we have not yet crossed the finish line

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of C

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

Prognostic factors in children with extragonadal malignant germ cell tumors: a pediatric intergroup study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Grou

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

Assessing the health care needs of adolescent and young adult cancer patients and survivors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

Use of paediatric versus adult oncology treatment centres by adolescents 15-19 years old: the Canadian Childhood Cancer Surveillance and Control Program

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

Management of osteosarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23060

7 January 2021

Identifiers

DOI

10.1002/CNCR.23060

1 reference

17 August 2017

1 reference